Patents by Inventor Shingo Tojo
Shingo Tojo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365589Abstract: The present invention provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1): wherein A1, A2, L1, L2, X, Z, R1 and R4 are as defined in the description, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 17, 2021Publication date: November 16, 2023Applicants: Sumitomo Pharma Co., Ltd., CARNA BIOSCIENCES, INC.Inventors: Shingo TOJO, Daisuke URABE, Hitoshi WATANABE, Wataru KAWAHATA, Hideki MORIYAMA, Yuko ASAMITSU
-
Patent number: 11661397Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: GrantFiled: October 16, 2020Date of Patent: May 30, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Publication number: 20230138851Abstract: The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I): wherein Q, R1, R2 and R3 are as defined in the description.Type: ApplicationFiled: January 28, 2021Publication date: May 4, 2023Applicant: CARNA BIOSCIENCES, INC.Inventors: Ayako SAWA, Wataru KAWAHATA, Yuko ASAMITSU, Masaaki SAWA, Yasuhiro IWATA, Hideki MORIYAMA, Shingo TOJO, Daisuke URABE
-
Publication number: 20210171440Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: ApplicationFiled: October 16, 2020Publication date: June 10, 2021Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Patent number: 10898469Abstract: The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof.Type: GrantFiled: February 23, 2017Date of Patent: January 26, 2021Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Tsuguteru Otsubo, Eiji Sugaru, Hiroki Yamaguchi, Nobuyuki Sawada, Chiang Jia Li
-
Patent number: 10807945Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: GrantFiled: June 21, 2016Date of Patent: October 20, 2020Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Patent number: 10703755Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.Type: GrantFiled: April 25, 2017Date of Patent: July 7, 2020Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Shingo Tojo, Yoshiaki Isobe, Eiji Ideue, Hiroaki Fujiwara, Daisuke Urabe
-
Publication number: 20190241550Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: October 11, 2018Publication date: August 8, 2019Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20190241569Abstract: The invention provides novel inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, and methods of making such compounds and compositions.Type: ApplicationFiled: November 30, 2018Publication date: August 8, 2019Inventors: Chiang Jia Li, Ji-Feng Liu, Wei Li, Amanda Gibeau, Harry Rogoff, Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20190169191Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.Type: ApplicationFiled: April 25, 2017Publication date: June 6, 2019Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Shingo TOJO, Yoshiaki ISOBE, Eiji IDEUE, Hiroaki FUJIWARA, Daisuke URABE
-
Publication number: 20190060282Abstract: The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: February 23, 2017Publication date: February 28, 2019Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Tsuguteru Otsubo, Eiji Sugaru, Hiroki Yamaguchi, Nobuyuki Sawada, Chiang Jia Li
-
Publication number: 20180230085Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: ApplicationFiled: June 21, 2016Publication date: August 16, 2018Inventors: Hitoshi Ban, Manabu Watanabe, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Patent number: 9828362Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: GrantFiled: February 27, 2017Date of Patent: November 28, 2017Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Publication number: 20170166552Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: ApplicationFiled: February 27, 2017Publication date: June 15, 2017Inventors: Hitoshi Ban, Manabu Watanabe, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Publication number: 20160075697Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: November 24, 2015Publication date: March 17, 2016Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20160031888Abstract: The invention provides compounds of Formula I as inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, wherein i.a. R2 is an optionally substituted heterocycle or optionally substituted aryl; and one of R4, R5, R6 and R7 is a substituted heterocycle or substituted aryl.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang Jia Li, Ji-feng Liu, Wei Li, Amanda Gibeau, Harry Rogoff, Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Patent number: 9227962Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: GrantFiled: March 13, 2014Date of Patent: January 5, 2016Assignee: Boston Biomedical, Inc.Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20140275076Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20110136801Abstract: The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: December 2, 2010Publication date: June 9, 2011Applicants: Dainippon Sumitomo Pharma Co. Ltd., AstraZeneca ABInventors: Yoshiaki Isobe, Mai Kasai, Tomoaki Nakamura, Shingo Tojo, Hirotaka Kurebayashi
-
Publication number: 20090082332Abstract: The present invention provides compounds of formula (I) wherein R1, Y1, X1, Z1, X2, Y2, A, Y3, n, R and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: September 20, 2006Publication date: March 26, 2009Inventors: Philip Abbot, Roger Victor Bonnert, Stephen Brough, Kamaldeep Chohan, Thomas McInally, Stephen Thom, Yoshiaki Isobe, Kei Nakamura, Shingo Tojo